PLX
Income statement / Annual
Last year (2024), Protalix BioTherapeutics, Inc.'s total revenue was $53.40 M,
a decrease of 18.47% from the previous year.
In 2024, Protalix BioTherapeutics, Inc.'s net income was $2.93 M.
See Protalix BioTherapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$53.40 M |
$65.49 M |
$47.64 M |
$38.35 M |
$62.90 M |
$54.69 M |
$34.24 M |
$21.08 M |
$9.20 M |
$4.36 M |
| Cost of Revenue |
$24.32 M
|
$22.98 M
|
$19.59 M
|
$16.35 M
|
$10.87 M
|
$10.90 M
|
$9.30 M
|
$15.23 M
|
$8.40 M
|
$730.00 K
|
| Gross Profit |
$29.08 M
|
$42.51 M
|
$28.05 M
|
$22.00 M
|
$52.03 M
|
$43.80 M
|
$24.94 M
|
$5.85 M
|
$801.00 K
|
$3.63 M
|
| Gross Profit Ratio |
0.54
|
0.65
|
0.59
|
0.57
|
0.83
|
0.8
|
0.73
|
0.28
|
0.09
|
0.83
|
| Research and Development Expenses |
$12.97 M
|
$17.09 M
|
$29.35 M
|
$29.73 M
|
$38.17 M
|
$44.62 M
|
$33.33 M
|
$28.83 M
|
$30.41 M
|
$20.03 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
-$13.58 M
|
-$4.02 M
|
-$5.09 M
|
-$5.97 M
|
$1.94 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$25.29 M
|
$16.75 M
|
$16.24 M
|
$15.87 M
|
$8.98 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.19 M
|
$14.96 M
|
$11.71 M
|
$12.73 M
|
$11.15 M
|
$9.90 M
|
$10.92 M
|
$11.53 M
|
$9.36 M
|
$7.28 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$6.80 M
|
$0.00
|
| Operating Expenses |
$25.16 M
|
$32.05 M
|
$41.06 M
|
$42.46 M
|
$49.32 M
|
$54.52 M
|
$44.25 M
|
$40.36 M
|
$33.96 M
|
$27.30 M
|
| Cost And Expenses |
$49.48 M
|
$55.03 M
|
$60.65 M
|
$58.81 M
|
$60.19 M
|
$65.41 M
|
$53.55 M
|
$55.60 M
|
$42.36 M
|
$28.03 M
|
| Interest Income |
$1.30 M
|
$1.29 M
|
$1.15 M
|
$401.00 K
|
$438.00 K
|
$407.00 K
|
$536.00 K
|
$188.00 K
|
$589.00 K
|
$123.00 K
|
| Interest Expense |
$1.06 M
|
$3.18 M
|
$2.53 M
|
$7.52 M
|
$9.67 M
|
$7.97 M
|
$7.69 M
|
$9.73 M
|
$4.19 M
|
$3.74 M
|
| Depreciation & Amortization |
$1.30 M
|
$1.19 M
|
$1.09 M
|
$1.12 M
|
$1.30 M
|
$1.62 M
|
$1.67 M
|
$1.92 M
|
$1.98 M
|
$2.37 M
|
| EBITDA |
$6.52 M |
$12.94 M |
-$10.78 M |
-$18.94 M |
$4.45 M |
-$8.69 M |
-$17.10 M |
-$71.80 M |
-$23.00 M |
-$21.18 M |
| EBITDA Ratio |
0.12
|
0.2
|
-0.23
|
-0.49
|
0.07
|
-0.16
|
-0.5
|
-3.41
|
-2.5
|
-4.85
|
| Operating Income Ratio |
0.07
|
0.16
|
-0.27
|
-0.53
|
0.04
|
-0.2
|
-0.56
|
-1.64
|
-3.61
|
-5.42
|
| Total Other Income/Expenses Net |
$237.00 K
|
-$1.89 M
|
-$1.38 M
|
-$7.12 M
|
-$9.23 M
|
-$7.56 M
|
-$7.15 M
|
-$48.92 M
|
$3.99 M
|
-$3.61 M
|
| Income Before Tax |
$4.15 M
|
$8.57 M
|
-$14.40 M
|
-$27.58 M
|
-$6.52 M
|
-$18.28 M
|
-$26.46 M
|
-$83.44 M
|
-$29.18 M
|
-$27.28 M
|
| Income Before Tax Ratio |
0.08
|
0.13
|
-0.3
|
-0.72
|
-0.1
|
-0.33
|
-0.77
|
-3.96
|
-3.17
|
-6.25
|
| Income Tax Expense |
$1.22 M
|
$254.00 K
|
$530.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$2.93 M
|
$8.31 M
|
-$14.93 M
|
-$27.58 M
|
-$6.52 M
|
-$18.28 M
|
-$26.46 M
|
-$83.44 M
|
-$29.37 M
|
$58.04 M
|
| Net Income Ratio |
0.05
|
0.13
|
-0.31
|
-0.72
|
-0.1
|
-0.33
|
-0.77
|
-3.96
|
-3.19
|
13.3
|
| EPS |
0.0404 |
0.12 |
-0.31 |
-0.62 |
-0.22 |
-1.23 |
-1.8 |
-6.5 |
-0.29 |
0.61 |
| EPS Diluted |
0.0366 |
0.1 |
-0.31 |
-0.62 |
-0.22 |
-1.23 |
-1.8 |
-6.5 |
-0.29 |
0.61 |
| Weighted Average Shares Out |
$72.53 M
|
$67.51 M
|
$48.47 M
|
$44.14 M
|
$29.15 M
|
$14.84 M
|
$14.71 M
|
$13.11 M
|
$101.39 M
|
$94.92 M
|
| Weighted Average Shares Out Diluted |
$81.06 M
|
$82.42 M
|
$48.47 M
|
$44.14 M
|
$29.15 M
|
$14.84 M
|
$14.71 M
|
$13.11 M
|
$101.39 M
|
$94.92 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
